GLPG Share Price Performance
€0
-22.86 (-100.00%)
Price €0
Fair Value€30.34
Share Pricen/a
Galapagos NV Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
GLPG Community Narratives
AN
Fair Value €30.34 9.6% undervalued intrinsic discount
Clinically Derisked Oncology Assets And Gilead Partnership Will Drive Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value €44.8 38.8% undervalued intrinsic discount
Cell Therapy Wind Down And Cash Reserves Will Drive A Leaner, Stronger Biotech Future
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value €19 44.3% overvalued intrinsic discount
Cell Therapy Exit And Single Late Stage Asset Will Drive Weaker Long Term Earnings
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Cell Therapy Exit And Single Late Stage Asset Will Drive Weaker Long Term Earnings
Catalysts About Galapagos Galapagos is a biotech company that is repositioning itself as a lean, cash rich platform focused on external business development and a limited internal pipeline. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€19
44.3% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-9.16% p.a.
Profit Margin
21.12%
Future PE
32.79x
Price in 2029
€22.55
Clinically Derisked Oncology Assets And Gilead Partnership Will Drive Long Term Earnings Potential
Catalysts About Galapagos Galapagos is repositioning as a capital rich, business development driven biotech company focused on acquiring and advancing clinically derisked assets. What are the underlying business or industry changes driving this perspective?Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€30.34
9.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-1.92% p.a.
Profit Margin
41.6%
Future PE
21.11x
Price in 2028
€36.08
Cell Therapy Wind Down And Cash Reserves Will Drive A Leaner, Stronger Biotech Future
Catalysts About Galapagos Galapagos is a biotechnology company focused on using its substantial capital base and deal-making expertise to build a differentiated, late stage therapeutic pipeline. What are the underlying business or industry changes driving this perspective?Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€44.8
38.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
0.57% p.a.
Profit Margin
1.25%
Future PE
9.62x
Price in 2028
€0.53
Trending Discussion
Recently Updated Narratives
AN
Cell Therapy Exit And Single Late Stage Asset Will Drive Weaker Long Term Earnings
Fair Value: €19 44.3% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinically Derisked Oncology Assets And Gilead Partnership Will Drive Long Term Earnings Potential
Fair Value: €30.34 9.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Cell Therapy Wind Down And Cash Reserves Will Drive A Leaner, Stronger Biotech Future
Fair Value: €44.8 38.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Galapagos NV Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 23, 2026
- -6.74
- -72.21%
- -154.70%
- 0%
About GLPG
- Founded
- 1999
- Employees
- 558
- CEO
- WebsiteView website
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
